keine Finanzberatung

RMD · ResMed

Sleep-apnea devices and masks plus out-of-hospital health software

Risiko 4/10 · LOW-MODERATE RISK · medtech category leader · $228.35 ▼ 0.37%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $228.35
  • Market cap $32.9B
  • P/E (ttm) 21.87
  • Div yield 1.16%
  • 52-wk range $180.27 – $284.87
  • Index rank #314 / —

Wichtigste Risiken

  • GLP-1 drugs shrink the long-term patient pool (Shareholders) — MED
  • Soft growth outlook persists beyond one year (Shareholders) — MED
  • Philips returns to full competitive strength (Shareholders) — MED
  • Reimbursement cuts on sleep and respiratory devices (Shareholders) — LOW

Fazit

A solid medtech franchise at a reasonable price — if you believe the weight-loss-drug scare stays a scare.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.